[Comment on the contribution by R. Hefner and P.-A. Fischer. Increase in Parkinson symptoms in treatment with calcium antagonists].
Philipps
G R
GR
D002121:Calcium Channel Blockers / Q000009:adverse effects*; D003495:Cyclandelate / Q000009:adverse effects; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*
D002121:Calcium Channel Blockers; D003495:Cyclandelate
Stellungnahme zum Beitrag von R. Hefner und P.-A. Fischer. Zunahme der Parkinson-Symptomatik unter Kalzium-Antagonisten.